Targeting the immune system to treat lung cancer: Rationale and clinical experience

Therapeutic Advances in Respiratory Disease

Volumn 9, Issue 3, 2015, Pages 105-120

  Guibert, Nicolas ^a   Delaunay, Myriam ^a   Mazières, Julien ^a  

^a SERVICE DE PNEUMOLOGIE   (France)

Author keywords

Immunotherapy; lung cancer; vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CD274 PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; LYMPHOCYTE ANTIGEN RECEPTOR; MAGEA3 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; MUCIN 1; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TELOMERASE; TUMOR ANTIGEN; TUMOR PROTEIN; DENDRITIC CELL VACCINE; DURVALUMAB; IPILIMUMAB; IPILIMUMAB PLUS NIVOLUMAB; MELANOMA ANTIGEN 3; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; PREDNISONE; TECEMOTIDE; TELOMERASE REVERSE TRANSCRIPTASE; TERTOMOTIDE; UNCLASSIFIED DRUG; ZASTUMOTIDE;

CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; PROCEDURES; REGULATORY T LYMPHOCYTE; TRANSPLANTATION; ACTIVE IMMUNIZATION; ADOPTIVE TRANSFER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG TARGETING; ENDOCRINE DISEASE; EX VIVO STUDY; GASTROINTESTINAL SYMPTOM; IMMUNE RESPONSE; LIVER DISEASE; LUNG CANCER; LUNG DISEASE; LUNG TOXICITY; LYMPHOCYTE ACTIVATION; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OXYGEN THERAPY; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SKIN DISEASE; SKIN TOXICITY; SURVIVAL RATE; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CTLA-4 ANTIGEN; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MUCIN-1; NEOPLASM PROTEINS; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TELOMERASE;

EID: 84930719096     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465815578349     Document Type: Review

References (86)

1. Akbay E. Koyama S. Carretero J. Altabef A. Tchaicha J. Christensen C. (2013) Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 3: 1355–1363.
2. Ansen S. Schultheis A.M. Hellmich M. Zander T. Brockmann M. Stoelben E. (2014) PD-L1 expression and genotype in non-small cell lung cancer. J Clin Oncol 32(Suppl.): abstract 7517.
3. Antonia S. Gettinger S. Chow L. Juergens R. Borghaei H. Shen Y. (2014) Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in firstline NSCLC: Interim phase I results. J Clin Oncol 32(Suppl.): abstract 8023.
4. Antonia S.J. Brahmer J. Gettinger S. Chow L. Juergens R. Shepherd F.A. (2014) Nivolumab (anti-PD-1; BMS- 936558, ONO-4538) in combination with platinum based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 32(Suppl.): abstract 8113.
5. Banchereau J. Palucka A. (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5: 296–306.
6. Barjaktarevic I. Qadir N. Suri A. Santamauro J. Stover D. (2013) Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. Chest 143: 858–861.
7. Barlesi F. Scherpereel A. Rittmeyer A. Pazzola A. Ferrer Tur N. Kim J. (2013) Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 31: 3004–3011.
8. Bazhenova L. Giaccone G. Nemunaitis J. Juhász E. Ramlau R. Van den Heuvel M. (2014) An international, multicenter, randomized, double-blind phase III study of maintenance belagenpumatucel-l in non-small cell lung cancer (NSCLC): updated analysis of patients enrolled within 12 weeks of completion of chemotherapy. J Clin Oncol 32 (Suppl.): abstract 8056.
9. Blackburn S. Shin H. Haining W. Zou T. Workman C. Polley A. (2009) Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 10: 29–37.
10. Brahmer J. (2013) Mini-oral presentation at WCLC 2013. J Thorac Oncol 8(Suppl. 2): abstract MO18.03.
11. Brahmer J. Horn L. Gandhi L. Spigel D. Antonia S.J. Rizvi N. (2014) Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis. J Clin Oncol 32(Suppl.): abstract 8112.
12. Brunsvig P. Kyte J. Kersten C. Sundstrøm S. Møller M. Nyakas M. (2011) Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res 17: 6847–6857.
13. Butts C. Socinski M. Mitchell P. Thatcher N. Havel L. Krzakowski M. (2014) Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 15: 59–68.
14. Calles A. Liao X. Sholl L. Butaney M. Rodig S. Freeman G.J. (2014) Differential expression of LKB1, PD-L1, and PD-L2 in KRAS-mutant nonsmall cell lung cancer in never-smokers. J Clin Oncol 32(Suppl.): abstract 8032.
15. Chen D. Mellman I. (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39: 1–10.
16. Chen D. Irving B. Hodi F. (2012) Molecular pathways: next-generation immunotherapy–inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 18: 6580–6587.
17. Chen L. (2004) Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4: 336–347.
18. Chow L. (2013) Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer. Am Soc Clin Oncol Educ Book. doi: 10.1200/EdBook_AM.2013.33.e280.
19. Darrasse-Jèze G. Deroubaix S. Mouquet H. Victora G. Eisenreich T. Yao K. (2009) Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med 31 206: 1853–1862.
20. Dasanu C. Sethi N. Ahmed N. (2012) Immune alterations and emerging immunotherapeutic approaches in lung cancer. Expert Opin Biol Ther 12: 923–937.
21. Delyon J. Mateus C. Lefeuvre D. Lanoy E. Zitvogel L. Chaput N. (2013) Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 24: 1697–1703.
22. Fong L. Small E. (2008) Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 26: 5275–5283.
23. Gangadhar T. Vonderheide R. (2014) Mitigating the toxic effects of anticancer immunotherapy. Nat Rev Clin Oncol 11: 91–99.
24. Garon E.B. Gandhi L. Rizvi N. Hui R. Balmanoukian A.S. Patnaik A. (2014) Antitumor activity of pembrolizumab (Pembro; MK-3475) and correlation with programmed death ligand 1 (PD-L1) expression in a pooled analysis of patients (pts) with advanced non-small cell lung carcinoma. Ann Oncol 25(5): 1–41. doi: 10.1093/annonc/mdu438.
25. Gettinger S. Herbst R. (2014) B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction. Cancer J 20: 281–289.
26. Gladwish A. Clarke K. Bezjak A. (2010) Spontaneous regression in advanced non-small cell lung cancer. BMJ Case Rep. doi: 10.1136/bcr.07.2010.3147.
27. Grande C. Villanueva M. Huidobro G. Casal J. (2007) Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment. Clin Transl Oncol 9: 578–581.
28. Hamid O. Carvajal R. (2013) Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opin Biol Ther 13: 847–861.
29. Herbst R. Gordon M. Fine G.D. Sosman J.A. Soria J.C. Hamid O. (2013) A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J Clin Oncol 31(Suppl.): abstract 3000.
30. Herbst R. Soria J. Kowanetz M. Fine G. Hamid O. Gordon M. (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515: 563–567.
31. Hilbe W. Dirnhofer S. Greil R. Wöll E. (2004) Biomarkers in non-small cell lung cancer prevention. Eur J Cancer Prev 13: 425–436.
32. Hochstrasser A. Benz G. Joerger M. Templeton A. Brutsche M. Früh M. (2012) Interstitial pneumonitis after treatment with pemetrexed: a rare event? Chemotherapy 58: 84–88.
33. Hodi F. Mihm M. Soiffer R. Haluska F. Butler M. Seiden M. (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100: 4712–4717.
34. Hodi F. O–Day S. McDermott D. Weber R. Sosman J. Haanen J. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711–723.
35. Horn L. (2013) Mini-oral presentation at WCLC 2013. J Thorac Oncol 8(Suppl. 2): abstract MO18.01.
36. Inoue A. Kunitoh H. Sekine I. Sumi M. Tokuuye K. Saijo N. (2001) Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. Int J Radiat Oncol Biol Phys 49: 649–655.
37. Kalos M. June C. (2013) Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39: 49–60.
38. Keir M. Butte M. Freeman G. Sharpe A. (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26: 677–704.
39. Kochenderfer J. Rosenberg S. (2013) Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 10: 267–276.
40. Konishi J. Yamazaki K. Kinoshita I. Isobe H. Ogura S. Sekine S. (2005) Analysis of the response and toxicity to gefitinib of non-small cell lung cancer. Anticancer Res 25: 435–441.
41. Liu V. White D. Zakowski M. Travis W. Kris M. Ginsberg M. (2007) Pulmonary toxicity associated with erlotinib. Chest 132: 1042–1044.
42. Lynch T. Bondarenko I. Luft A. Serwatowski P. Barlesi F. Chacko R. (2012) Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30: 2046–2054.
43. Marincola F. Jaffee E. Hicklin D. Ferrone S. (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74: 181–273.
44. McLaughlin J. Schalper K. Carvajal-Hausdorf D. Velcheti V. Haack H. Silver M. (2014) Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC). J Clin Oncol 32(Suppl.): abstract 8064.
45. Mellman I. Coukos G. Dranoff G. (2011) Cancer immunotherapy comes of age. Nature 480: 480–489.
46. Morris J. Rossi G. Harold N. Tennant L. Ramsey W. Vahanian N. (2013) Potential chemo-sensitization effect of tergenpumatucel-L immunotherapy in treated patients with advanced non-small cell lung cancer. J Clin Oncol 31(Suppl.): abstract 8094.
47. Motz G. Coukos G. (2013) Deciphering and reversing tumor immune suppression. Immunity 39: 61–73.
48. Naiyer A. Rizvi N.A. Chow L. Borghaei H. Shen Y. Harbison C. (2014) Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. J Clin Oncol 32(Suppl.): abstract 8022.
49. Nemunaitis J. Dillman R. Schwarzenberger P. Senzer N. Cunningham C. Cutler J. (2006) Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 24: 4721–4730.
50. Nirschl C. Drake C. (2013) Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res 19: 4917–4924.
51. Palucka K. Banchereau J. (2013) Dendritic-cell-based therapeutic cancer vaccines. Immunity 39: 38–48.
52. Parry R. Chemnitz J. Frauwirth K. Lanfranco A. Braunstein I. Kobayashi S. (2005) CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 25: 9543–9553.
53. Quoix E. Losonczy G. Forget F. Chouaid C. Papai Z. Gervais R. (2014) 1055PD - TIME, a phase 2b/3 study evaluating TG4010 in combination with first line therapy in advanced non small cell lung cancer (NSCLC). Phase 2b results. ESMO: abstract 5152. Available at: https://www.webges.com/cslide/library/esmo/browse/search/8eQ”\l”9f9A02wQ” https://www.webges.com/cslide/library/esmo/browse/search/8eQ#9f9A02wQ
54. Quoix E. Ramlau R. Westeel V. Papai Z. Madroszyk A. Riviere A. (2011) Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 12: 1125–1133.
55. Qureshi O. Zheng Y. Nakamura K. Attridge K. Manzotti C. Schmidt E. (2011) Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332: 600–603.
56. Rizvi N. Chow L. Borghaei H. Shen Y. Harbison C. Alaparthy S. (2014) Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. J Clin Oncol 32(Suppl.): abstract 8022.
57. Rizvi N.A. Mazières J. Planchard D. Stinchcombe T.E. Dy G.K. Antonia S.J. (2015) Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16(3): 257–265.
58. Roychowdhury D. Cassidy C. Peterson P. Arning M. (2002) A report on serious pulmonary toxicity associated with gemcitabine-based therapy. Invest New Drugs 20: 311–315.
59. Salvi S. Fontana V. Boccardo S. Merlo D. Margallo E. Laurent S. (2012) Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunol Immunother 61: 1463–1472.
60. Sandler A. Gray R. Perry M. Brahmer J. Schiller J. Dowlati A. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542–2550.
61. Schreiber R. Old L. Smyth M. (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565–1570.
62. Scott J. (2014) Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 32(Suppl.): abstract 8113.
63. Segal N. Antonia S.J. Brahmer J. Maio M. Blake-Haskins A. Li X. (2014) Preliminary data from a multiarm expansion study of MEDI4736, an anti-PD-L1 antibody. J Clin Oncol 32(Suppl.): abstract 3002.
64. Slingluff C. (2011) The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J 17: 343–350.
65. Spiegel D. Gettinger S. Horn L. Herbst R.S. Gandhi L. Gordon M. (2013) Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 31(Suppl.): abstract 8008.
66. Steinman R. Hawiger D. Nussenzweig M. (2003) Tolerogenic dendritic cells. Annu Rev Immunol 21: 685–711.
67. Steinman R. Turley S. Mellman I. Inaba K. (2000) The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 191: 411–416.
68. Sterlacci W. Wolf D. Savic S. Hilbe W. Schmid T. Jamnig H. (2012) High transforming growth factor β expression represents an important prognostic parameter for surgically resected non-small cell lung cancer. Hum Pathol 43: 339–349.
69. Sundar R. Soong R. Cho B. Brahmer J. Soo R. (2014) Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 85: 101–109.
70. Taube J. Anders R. Young G. Xu H. Sharma R. McMiller T. (2012) Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4: 127ra37.
71. Topalian S. Hodi F. Brahmer J. Gettinger S. Smith D. McDermott D. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443–2454.
72. Tumeh P. Harview C. Yearley J. Shintaku I. Taylor E. Robert L. (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515: 568–571.
73. Vacchelli E. Aranda F. Eggermont A. Galon J. Sautès-Fridman C. Cremer I. (2014) Trial Watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology 3: e27878.
74. Vansteenkiste J. Cho B. Vanakesa T. De Pas T. Zielinski M. Kim M. (2014) MAGRIT, a double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of the recMAGE-A3 + AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC). Ann Oncol 25(Suppl. 4): iv409–iv416.
75. Vansteenkiste J. Zielinski M. Linder A. Dahabreh J. Gonzalez E. Malinowski W. (2013) Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. 31: 2396–2403.
76. Vinageras N. de la Torre A. Rodríguez O. Ferrer C. (2008) Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 26: 1452–1458.
77. Weber J. Kåhler K. Hauschild A. (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30: 2691–2697.
78. Weber J. Thompson J. Hamid O. Minor D. Amin A. Ron I. (2009) A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 15: 5591–5598.
79. Wesselius L. Wheaton D. Manahan-Wahl L. Sherard S. Taylor S. Abdou N. (1987) Lymphocyte subsets in lung cancer. Chest 91: 725–729.
80. Whiteside T. (2010) Immune responses to malignancies. J Allergy Clin Immunol 125(2 Suppl. 2): S272's283.
81. Wolchok J. Hoos A. O–Day S. Weber J. Hamid O. Lebbé C. (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15: 7412–7420.
82. Wolchok J. Kluger H. Callahan M. Postow M.A. Gordon R.A. Segal N. (2013) Safety and clinical activity of nivolumab (anti-PD-1, BMS 936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL). J Clin Oncol 31(15 Suppl.): abstract 9012.
83. Yang C. Lin M. Chang Y. Wu C. Yang P. (2014) Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 50: 1361–1369.
84. Zheng H. Li Y. Wang X. Zhang X. Wang X. (2010) [Expression and significance of gp96 and immune-related gene CTLA-4, CD8 in lung cancer tissues]. Zhongguo Fei Ai Za Zhi 13: 790–794.
85. Zikos T. Donnenberg A. Landreneau R. Luketich J. Donnenberg V. (2011) Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in non-small cell lung cancer. Cancer Immunol Immunother 60: 819–827.
86. Zou W. Chen L. (2008) Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8: 467–477.